A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Scynexis Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 10,300 shares of SCYX stock, worth $10,403. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,300
Previous 15,900 35.22%
Holding current value
$10,403
Previous $31,000 51.61%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.4 - $2.77 $46,251 - $91,512
33,037 New
33,037 $66,000
Q3 2023

Nov 14, 2023

BUY
$1.93 - $3.64 $218 - $411
113 New
113 $0
Q4 2022

Feb 14, 2023

SELL
$1.46 - $2.94 $57,919 - $116,632
-39,671 Reduced 92.08%
3,413 $5,000
Q3 2022

Nov 14, 2022

BUY
$1.83 - $2.93 $50,345 - $80,607
27,511 Added 176.66%
43,084 $103,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.